FDA Approves LICART — IBSA Pharma Inc.
IBSA Pharma Inc. secured FDA approval for its topical arthritis drug LICART in December 2018, expanding its product portfolio and increasing market share within the legal-medicine sector.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day